16.35-18.10 ADVANCING IN TECHNOLOGY AND APPLICATIONS: SESSION I

16:35 – 16:50 Nucleosomas como nueva prueba basada en sangre para caracterizar tumores
Nucleosomes as new blood based test to characterize tumours

Mr. Mark Eccleston, Business Development Director at Volition. Inses, Belgium

Presentation

16:50 – 17:05 Perfiles genómicos utilizados en biopsia líquida
Genomic profi les employed in liquid biopsy

Dr. Emiliano Calvo, START Madrid CIOCC, Centro Integral Oncológico Clara Campal. Madrid

Presentation

17:05 – 17:20 Sistemas de microfluídica para aislamiento de CTCs
Microfl uidic technologies for CTCs isolation
Dra. Lorena Diéguez, International Iberian Nanotechnology Laboratory – INL. Braga, Portugal

Presentación

17:20 – 17:35 ERASE-SEQ: Detección precisa de variantes somáticas de baja frecuencia en cfDNA
ERASE-Seq: accurate detection of low frequency domatic variants in cfDNA

Mr. Cristian Ionescu, Chief Technology Offi cer at Fluxion Biosciences. Alameda, California, USA

Presentation
18.10-18.20 Public procurement of innovation applied to oncology: Código 100 innovation plan

Dr. Luis León, Axencia de Coñecemento en Saúde-ACIS. Santiago de Compostela

Presentation
18.40-20.00 ADVANCING IN TECHNOLOGY AND APPLICATIONS: SESSION II

18:55 – 19:10 La experiencia de la biopsia líquida de OncoBEAM en la práctica clínica del mundo real
The OncoBEAM liquid biopsy experience in real-world clinical practice
Mr. Frederick S. Jones, Director Medical Affairs Liaison at Sysmex-Inostics. Mundelein, Illinois, USA

Presentation

19:10 – 19:25 Enriquecimiento CTC con PARSORTIX™: clinical applicationsCTC
Enrichment with PARSORTIX™: clinical applications
Dra. Eva Obermayr, Medical University Vienna. Austria

Presentation

Passatge Batlló, 15
Barcelona

T. +34 93 451 17 24
F. 93 451 43 66

info@tacticsmd.net
www.tacticsmd.net


San Francisco Hotel Monumento
Campillo de San Francisco, 3
Santiago de Compostela
www.sanfranciscohm.com